Also, China has become more integrated into the international drug regulatory system since joining the ICH in 2017. Thus, China\’s regulatory environment is improving for overseas new drugs to seek marketing authorization.
With total drug sales scoring 1,558.5 billion yuan (circa 214.9 billion USD) in 2021, China continues attracting drug companies as a considerable pharmaceutical market. To help pharma companies register new drugs in China, this webinar will introduce the regulatory requirements for submitting new drug applications (NDAs) to CDE.